Combined therapy with intravenous immunoglobulin (IVIg) and intravenous methylprednisolone (IVMP) provided better efficacy outcomes than either therapy alone as initial therapy in anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis.
Why this matters ?
NMDAR encephalitis is a novel and severe autoimmune encephalitis characterized by the presence of neuronal surface autoantibodies targeting the NMDAR.
Treatments that downregulate immune responses, including high-dose IVMP, IVIg, or both have demonstrated good recovery rates of 70–80%.
However, how the varying treatment options differ in response rate, speed of recovery, prognosis, recurrence, and safety remains unclear.